Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Thermo Fisher Scientific (NY:TMO)

472.64 -8.10 (-1.68%)
Official Closing Price Updated: 4:10 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Thermo Fisher Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Morgan Stanley Reveals Top 20 AI-Driven Stocks as Adoption Hits Critical Mass
Katy Huberty, the Global Head of Research at Morgan Stanley, has spotlighted 20 stocks from companies that are likely to see significant benefits from the adoption of Artificial Intelligence (AI). 
Via Benzinga
Topics Artificial Intelligence
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely. 
Via Benzinga
Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase
Companies with strong cash flow and a history of impressing Wall Street analysts may make excellent prospects for 2025; TMO, ET, and NTES are three to watch. 
Via MarketBeat
Thermo Fisher Scientific Unusual Options Activity For January 21
 
Via Benzinga
$100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
How Is The Market Feeling About Thermo Fisher Scientific?
 
Via Benzinga
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years
 
Via Benzinga
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. 
Via News Direct
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years
 
Via Benzinga
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results. 
Via Benzinga
Check Out What Whales Are Doing With TMO
 
Via Benzinga
Market Whales and Their Recent Bets on TMO Options
 
Via Benzinga
Earnings Outlook For Thermo Fisher Scientific
 
Via Benzinga
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test 
Via News Direct
The Oncology Bet Is Already Paying Off For Pfizer
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%... 
Via Benzinga
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening 
Via News Direct
Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
 
Via Benzinga
Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
 
Via Benzinga
(TMO) - Analyzing Thermo Fisher Scientific's Short Interest
 
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
 
Via Benzinga
Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?
Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest... 
Via Benzinga
Thermo Fisher Scientific (TMO) Q3 2024 Earnings Call Transcript
TMO earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives
Thermo Fisher Scientific's Q3 revenue of $10.59 billion missed expectations. Adjusted EPS beat estimates but dropped year-over-year. Guidance for 2024 remains reaffirmed. 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. 
Via Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential
Stephens initiated coverage on Thermo Fisher Scientific with an Overweight rating and $680 price target. The firm highlights the company's biopharma expansion, M&A strategy, and key growth areas like... 
Via Benzinga
Momentum Investing Gives You An Edge, Until It Doesn’t
Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.